These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28883724)

  • 1. Nanomedicinal products: a survey on specific toxicity and side effects.
    Brand W; Noorlander CW; Giannakou C; De Jong WH; Kooi MW; Park MV; Vandebriel RJ; Bosselaers IE; Scholl JH; Geertsma RE
    Int J Nanomedicine; 2017; 12():6107-6129. PubMed ID: 28883724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements.
    Giannakou C; Park MV; de Jong WH; van Loveren H; Vandebriel RJ; Geertsma RE
    Int J Nanomedicine; 2016; 11():2935-52. PubMed ID: 27382281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls.
    Giannakou C; Park MVDZ; Bosselaers IEM; de Jong WH; van der Laan JW; van Loveren H; Vandebriel RJ; Geertsma RE
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1633. PubMed ID: 32266791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro toxicity assessment of oral nanocarriers.
    Ciappellano SG; Tedesco E; Venturini M; Benetti F
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):381-401. PubMed ID: 27544694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin in ovarian cancer.
    Green AE; Rose PG
    Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.
    Gaitanis A; Staal S
    Methods Mol Biol; 2010; 624():385-92. PubMed ID: 20217610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
    Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
    Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in nano drugs for cancer chemotherapy.
    Ali I; Rahis-Uddin ; Salim K; Rather MA; Wani WA; Haque A
    Curr Cancer Drug Targets; 2011 Feb; 11(2):135-46. PubMed ID: 21158724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
    Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
    Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
    Azanza JR; Sádada B; Reis J
    Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
    Petersen GH; Alzghari SK; Chee W; Sankari SS; La-Beck NM
    J Control Release; 2016 Jun; 232():255-64. PubMed ID: 27108612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
    Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
    Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
    Gabizon AA; Patil Y; La-Beck NM
    Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology.
    Oberdörster G
    J Intern Med; 2010 Jan; 267(1):89-105. PubMed ID: 20059646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal drug delivery system from laboratory to clinic.
    Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
    J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Nanoparticle Surface on the HPLC Elution Profile of Liposomal Nanoparticles.
    Itoh N; Yamamoto E; Santa T; Funatsu T; Kato M
    Pharm Res; 2016 Jun; 33(6):1440-6. PubMed ID: 26928667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.